2025-09-18 – Press Releases – www.prnewswire.com
YANTAI, China, Sept. 18, 2025 /PRNewswire/ — RemeGen (688331.SH/09995.HK) announced that the 48-week open-label extension (OLE) data from China Phase III clinical study of telitacicept (RC18, brand name: 泰爱®, a BLyS/APRIL dual-target fusion protein innovative drug independently developed…
